BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 15459302)

  • 21. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.
    Aspinall AI; Pinto A; Auer IA; Bridges P; Luider J; Dimnik L; Patel KD; Jorgenson K; Woodman RC
    Blood Cells Mol Dis; 1999; 25(3-4):227-38. PubMed ID: 10575548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib.
    Bi LL; Pan G; Atkinson TP; Zheng L; Dale JK; Makris C; Reddy V; McDonald JM; Siegel RM; Puck JM; Lenardo MJ; Straus SE
    BMC Med Genet; 2007 Jul; 8():41. PubMed ID: 17605793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoimmune lymphoproliferative syndrome in a patient with a new minimal deletion in the death domain of the FAS gene.
    Gualco G; van den Berg A; Koopmans S; Bacchi LM; Carneiro SS; Ruiz E; Vecchi AP; Chan JK
    Hum Pathol; 2008 Jan; 39(1):137-41. PubMed ID: 18070632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inactivation of the Fas gene by Alu insertion: retrotransposition in an intron causing splicing variation and autoimmune lymphoproliferative syndrome.
    Tighe PJ; Stevens SE; Dempsey S; Le Deist F; Rieux-Laucat F; Edgar JD
    Genes Immun; 2002 Oct; 3 Suppl 1():S66-70. PubMed ID: 12215906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation.
    Sleight BJ; Prasad VS; DeLaat C; Steele P; Ballard E; Arceci RJ; Sidman CL
    Bone Marrow Transplant; 1998 Aug; 22(4):375-80. PubMed ID: 9722073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A genetic disorder of lymphocyte apoptosis involving the fas pathway: the autoimmune lymphoproliferative syndrome.
    Fleisher TA; Straus SE; Bleesing JJ
    Curr Allergy Asthma Rep; 2001 Nov; 1(6):534-40. PubMed ID: 11895618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.
    Fisher GH; Rosenberg FJ; Straus SE; Dale JK; Middleton LA; Lin AY; Strober W; Lenardo MJ; Puck JM
    Cell; 1995 Jun; 81(6):935-46. PubMed ID: 7540117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoimmune lymphoproliferative syndrome: a syndrome associated with inherited genetic defects that impair lymphocytic apoptosis--CT and US features.
    Avila NA; Dwyer AJ; Dale JK; Lopatin UA; Sneller MC; Jaffe ES; Puck JM; Straus SE
    Radiology; 1999 Jul; 212(1):257-63. PubMed ID: 10405750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HLA B44 is associated with decreased severity of autoimmune lymphoproliferative syndrome in patients with CD95 defects (ALPS type Ia).
    Vacek MM; Schäffer AA; Davis J; Fischer RE; Dale JK; Adams S; Straus SE; Puck JM
    Clin Immunol; 2006 Jan; 118(1):59-65. PubMed ID: 16257267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
    Sneller MC; Wang J; Dale JK; Strober W; Middelton LA; Choi Y; Fleisher TA; Lim MS; Jaffe ES; Puck JM; Lenardo MJ; Straus SE
    Blood; 1997 Feb; 89(4):1341-8. PubMed ID: 9028957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Residual CD95-pathway function in children with autoimmune lymphoproliferative syndrome is independent from clinical state and genotype of CD95 mutation.
    Fuchs H; Posovszky C; Lahr G; van der Werff ten Bosch J; Boehler T; Debatin KM
    Pediatr Res; 2009 Feb; 65(2):163-8. PubMed ID: 18948840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The autoimmune lymphoproliferative syndrome: a disorder of programmed cell death].
    Seegers D; Peña AS; Bouma G
    Ned Tijdschr Geneeskd; 2004 Feb; 148(8):371-6. PubMed ID: 15032090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function.
    Magerus-Chatinet A; Stolzenberg MC; Loffredo MS; Neven B; Schaffner C; Ducrot N; Arkwright PD; Bader-Meunier B; Barbot J; Blanche S; Casanova JL; Debré M; Ferster A; Fieschi C; Florkin B; Galambrun C; Hermine O; Lambotte O; Solary E; Thomas C; Le Deist F; Picard C; Fischer A; Rieux-Laucat F
    Blood; 2009 Mar; 113(13):3027-30. PubMed ID: 19176318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoimmune lymphoproliferative syndrome presenting with glomerulonephritis.
    Kanegane H; Vilela MM; Wang Y; Futatani T; Matsukura H; Miyawaki T
    Pediatr Nephrol; 2003 May; 18(5):454-6. PubMed ID: 12736807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis.
    Infante AJ; Britton HA; DeNapoli T; Middelton LA; Lenardo MJ; Jackson CE; Wang J; Fleisher T; Straus SE; Puck JM
    J Pediatr; 1998 Nov; 133(5):629-33. PubMed ID: 9821419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The role of CD95 (APO-1/Fas) mutations in lymphoproliferative and malignant lymphatic diseases].
    Beltinger C; Böhler T; Schrappe M; Ludwig WD; Debatin KM
    Klin Padiatr; 1998; 210(4):153-8. PubMed ID: 9743945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical, immunological, and pathological consequences of Fas-deficient conditions.
    Le Deist F; Emile JF; Rieux-Laucat F; Benkerrou M; Roberts I; Brousse N; Fischer A
    Lancet; 1996 Sep; 348(9029):719-23. PubMed ID: 8806292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma.
    Shin MS; Park WS; Kim SY; Kim HS; Kang SJ; Song KY; Park JY; Dong SM; Pi JH; Oh RR; Lee JY; Yoo NJ; Lee SH
    Am J Pathol; 1999 Jun; 154(6):1785-91. PubMed ID: 10362803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Autoimmune lymphoproliferative syndrome(ALPS)].
    Kasahara Y
    Ryoikibetsu Shokogun Shirizu; 2000; (31):168-71. PubMed ID: 11269048
    [No Abstract]   [Full Text] [Related]  

  • 40. Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations.
    Rieux-Laucat F; Blachère S; Danielan S; De Villartay JP; Oleastro M; Solary E; Bader-Meunier B; Arkwright P; Pondaré C; Bernaudin F; Chapel H; Nielsen S; Berrah M; Fischer A; Le Deist F
    Blood; 1999 Oct; 94(8):2575-82. PubMed ID: 10515860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.